価格表
在庫・価格 : 2025年04月26日 14時16分 現在
商品名 | 商品コード | メーカー | 包装 | 価格 | 在庫 | リスト |
---|---|---|---|---|---|---|
Anti-VEGF, Mouse-Mono(VG1) データシート※最新のデータシートでない場合があります |
NB100-664SS |
NOVノバス バイオロジカルス Novus biologicals, LLC |
0.025 mg | ¥48,000 |
無 (未発注) |
追加 |
在庫・価格 : 2025年04月26日 14時16分 現在
Anti-VEGF, Mouse-Mono(VG1)
- 商品コード:NB100-664SS
- メーカー:NOV
- 包装:0.025mg
- 価格: ¥48,000
- 在庫:無(未発注)
使用文献
- No.: 1
-
文献情報:
Turley H et al. Expression of VEGF in routinely fixed material using a new monoclonal antibody VG1. J. Pathol. 1998 Nov;186(3):313-8
Turley H et al
1998/01/01
-
備考:
-
参照:
- No.: 2
-
文献情報:
Giatromanolaki A et al. DEC1 (STRA13) protein expression relates to hypoxia- inducible factor 1-alpha and carbonic anhydrase-9 overexpression in non-small cell lung cancer. J. Pathol. 2003 Jun;200(2):222-8
Giatromanolaki A et al
2003/01/01
-
備考:
-
参照:
- No.: 3
-
文献情報:
Van der Auwera I et al. Increased angiogenesis and lymphangiogenesis in inflammatory versus noninflammatory breast cancer by real-time reverse transcriptase-PCR gene expression quantification. Clin. Cancer Res. 2004 Dec;10(23):7965-71
Van der Auwera I et al
2004/01/01
-
備考:
Applications: -
参照:
- No.: 4
-
文献情報:
Adams J et al. Vascular endothelial growth factor (VEGF) in breast cancer: comparison of plasma, serum, and tissue VEGF and microvessel density and effects of tamoxifen. Cancer Res. 2000 Jun;60(11):2898-905
Adams J et al
2000/01/01
-
備考:
Applications: -
参照:
- No.: 5
-
文献情報:
Couvelard A et al. Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression. Br. J. Cancer 2005 Jan;92(1):94-101
Couvelard A et al
2005/01/01
-
備考:
Applications: -
参照:
- No.: 6
-
文献情報:
Kakolyris S et al. Assessment of vascular maturation in non-small cell lung cancer using a novel basement membrane component, LH39: correlation with p53 and angiogenic factor expression. Cancer Res. 1999 Nov;59(21):5602-7
Kakolyris S et al
1999/01/01
-
備考:
Applications: -
参照:
- No.: 7
-
文献情報:
Koukourakis MI et al. Vascular endothelial growth factor/KDR activated microvessel density versus CD31 standard microvessel density in non-small cell lung cancer. Cancer Res. 2000 Jun;60(11):3088-95
Koukourakis MI et al
2000/01/01
-
備考:
Applications: -
参照:
- No.: 8
-
文献情報:
Giatromanolaki A et al. Coexpression of MUC1 glycoprotein with multiple angiogenic factors in non-small cell lung cancer suggests coactivation of angiogenic and migration pathways. Clin. Cancer Res. 2000 May;6(5):1917-21
Giatromanolaki A et al
2000/01/01
-
備考:
Applications: -
参照:
- No.: 9
-
文献情報:
Giatromanolaki A et al. Vascular endothelial growth factor, wild-type p53, and angiogenesis in early operable non-small cell lung cancer. Clin. Cancer Res. 1998 Dec;4(12):3017-24
Giatromanolaki A et al
1998/01/01
-
備考:
Species: Human, Applications: IHC -
参照:
- No.: 10
-
文献情報:
O'Byrne KJ et al. Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer. Br. J. Cancer 2000 Apr;82(8):1427-32
O'Byrne KJ et al
2000/01/01
-
備考:
Species: Human, Applications: IHC-P, WB -
参照:
- No.: 11
-
文献情報:
Zhang HT et al. The 121 amino acid isoform of vascular endothelial growth factor is more strongly tumorigenic than other splice variants in vivo. Br. J. Cancer 2000 Jul;83(1):63-8
Zhang HT et al
2000/01/01
-
備考:
Applications: -
参照:
- No.: 12
-
文献情報:
Kapsoritakis A et al. Vascular endothelial growth factor in inflammatory bowel disease. Int J Colorectal Dis 2003 Sep;18(5):418-22
Kapsoritakis A et al
2003/01/01
-
備考:
Applications: -
参照:
- No.: 13
-
文献情報:
Giatromanolaki A et al. Hypoxia inducible factor 1alpha and 2alpha overexpression in inflammatory bowel disease. J. Clin. Pathol. 2003 Mar;56(3):209-13
Giatromanolaki A et al
2003/01/01
-
備考:
Applications: -
参照:
- No.: 14
-
文献情報:
Salgado R et al. Arterio-venous gradients of IL-6, plasma and serum VEGF and D-dimers in human cancer. Br. J. Cancer 2002 Dec;87(12):1437-44
Salgado R et al
2002/01/01
-
備考:
Applications: -
参照:
- No.: 15
-
文献情報:
Hong DS et al. A phase 1 dose escalation, pharmacokinetic, and pharmacodynamic evaluation of eIF-4E antisense oligonucleotide LY2275796 in patients with advanced cancer. Clin. Cancer Res. 2011 Oct;17(20):6582-91
Hong DS et al
2011/01/01
-
備考:
Applications: -
参照:
- No.: 16
-
文献情報:
Ptaszynska MM et al. Positive feedback between vascular endothelial growth factor-A and autotaxin in ovarian cancer cells. Mol. Cancer Res. 2008 Mar;6(3):352-63
Ptaszynska MM et al
2008/01/01
-
備考:
Species: Human, Applications: WB -
参照:
- No.: 17
-
文献情報:
Giatromanolaki A et al. Vascular endothelial growth factor (VEGF) expression in operable gallbladder carcinomas. Eur J Surg Oncol 2003 Dec;29(10):879-83
Giatromanolaki A et al
2003/01/01
-
備考:
Applications: -
参照:
- No.: 18
-
文献情報:
Tam JC et al. A Chinese 2-herb formula (NF3) promotes hindlimb ischemia-induced neovascularization and wound healing of diabetic rats. J. Diabetes Complicat. ;28(4):436-47
Tam JC et al
-
備考:
Species: Rat, Applications: IHC-Fr -
参照:
- No.: 19
-
文献情報:
Fedorova LV et al. Peroxisome proliferator-activated receptor δ agonist, HPP593, prevents renal necrosis under chronic ischemia. PLoS ONE 2013;8(5):e64436
Fedorova LV et al
2013/01/01
-
備考:
Species: Rat, Applications: WB -
参照:
- No.: 20
-
文献情報:
Kunze D et al. Antisense-mediated inhibition of survivin, hTERT and VEGF in bladder cancer cells in vitro and in vivo. Int. J. Oncol. 2008 May;32(5):1049-56
Kunze D et al
2008/01/01
-
備考:
Species: Mouse, Applications: IHC-P -
参照: